Close Menu

NEW YORK (GenomeWeb) – Sygnis today reported a 64 percent increase in its first quarter revenues on strong sales of its research kits and devices.

For the three-month period ended March 31, the company's revenues rose to €2.3 million ($2.8 million) from €1.4 million in the same quarter the year before.

The Heidelberg, Germany-based firm posted a Q1 net loss of €322,000, or €.01 per share, down 73 percent from a loss of €1.2 million, or €.03 per share in the year-ago period.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.

Sponsored by

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Sponsored by

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.